Please assess the completion status of the following clinical trial:

Trial Title: Carbetocin at Elective Cesarean Delivery Part 3

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients planned for elective cesarean delivery under spinal anesthesia~* Patients who give written informed consent to participate~Exclusion Criteria:~* Patients who refuse to give written informed consent~* Patients who claim allergy or hypersensitivity to carbetocin or oxytocin~* Patients with conditions that predispose to uterine atony and postpartum hemorrhage such as placenta previa, multiple gestation, preeclampsia, eclampsia, macrosomia, polyhydramnios, uterine fibroids, previous history of uterine atony and postpartum bleeding, or bleeding diathesis.~* Patients with hepatic, renal, and vascular disease~* Patients requiring general anesthesia prior to the administration of the study drug.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Carbetocin 100mcg (Type: ACTIVE_COMPARATOR): Carbetocin 100mcg, once following delivery of the fetal head.
- Carbetocin 20mcg (Type: ACTIVE_COMPARATOR): Carbetocin 20mcg, once following delivery of the fetal head.
- Carbetocin 15mcg (Type: ACTIVE_COMPARATOR): Carbetocin 15mcg, once following delivery of the fetal head.
- Carbetocin 10mcg (Type: ACTIVE_COMPARATOR): Carbetocin 10mcg, following delivery of the fetal head.
- Carbetocin 5mcg (Type: ACTIVE_COMPARATOR): Carbetocin 5mcg, following delivery of the fetal head.
- Carbetocin 2mcg (Type: ACTIVE_COMPARATOR): Carbetocin 2mcg, following delivery of the fetal head.

Based on this trial design, predict the completion outcome and termination type (if applicable).